Joint venture to combine artificial intelligence with biosciences’ dataset to identify novel therapy targets.
Standigm, an organization specializing in artificial intelligence (AI), and Nashville Biosciences, a subsidiary of Vanderbilt University Medical Center (VUMC), have revealed plans to collaborate on early drug discovery research. Under the agreement, Standigm will use Nashville Bioscience's extensive, de-identified genomic and clinical data to build new, customized AI models for drug discovery, with the goal of accelerating early-stage drug development.
"We are tremendously excited to work with Nashville Biosciences to enhance our AI platforms so we can expedite early drug discovery with better insights," said Carl Foster, chief business officer at Standigm. "Data is undoubtedly a pivotal part of AI drug discovery. Leveraging Nashville Bioscience's data will add great value to our platforms, enabling us to make the most of customizable and explainable features. We will also be able to better understand the relationship between genetic variants and corresponding phenotypes."
Reference: Standigm and Nashville Biosciences join to revolutionize early drug discovery. PR Newswire. August 10, 2023. Accessed August 11, 2023. https://www.prnewswire.com/news-releases/standigm-and-nashville-biosciences-join-to-revolutionize-early-drug-discovery-301897580.html